“The study identified a fecal microbiome signature that robustly detects pancreatic cancer at high disease specificity,” Nuria Malats, MD, PhD, study author and head of the genetic and molecular epidemiology group at the Spanish National Cancer Research Center in Madrid, told Healio. “The fact that this uses noninvasive obtained samples (stool) makes this panel a potential test towards cost-effective [pancreatic ductal adenocarcinoma (PDAC)] screening and monitoring.” Read more . . .
Fecal microbiota-based screening may help with early detection of pancreatic ductal adenocarcinoma, according to a study published in Gut.